MedTrace Logo

Comarum Palustre in Knee Osteoarthritis and Diabetes

NCT03530930 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-05-15

No results posted yet for this study

Summary

The study evaluates analgesic, antiinflammatory and metabolic effects of Comarum palustre in patients with knee osteoarthritis (OA) and diabetes mellitus. Patients with osteoarthritis will receive Comarum palustre together with conventional treatment of osteoarthritis and diabetes.

Conditions

Interventions

DRUG

Comarum Palustre

Comarum Palustre tablets 500 mg BID, 1 month

Sponsors & Collaborators

  • Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology

    lead OTHER

Principal Investigators

  • Ivan Shirinsky · Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-29
Primary Completion
2018-11-25
Completion
2018-11-25

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03530930 on ClinicalTrials.gov